Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

101. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel 19176635 2009 03 31 2009 05 04 2014 12 10 1488-2329 180 7 2009 Mar 31 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. 713-8 10.1503/cmaj.082001 Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical (...) ) were matched to cases on age, percutaneous coronary intervention and a validated risk score. We categorized exposure to proton pump inhibitors before the index date as current (within 30 days), previous (31-90 days) or remote (91-180 days). Among 13 636 patients prescribed clopidogrel following acute myocardial infarction, we identified 734 cases readmitted with myocardial infarction and 2057 controls. After extensive multivariable adjustment, current use of proton pump inhibitors was associated

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

102. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials

Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment (...) comparison of randomized controlled trials Edwards SJ, Lind T, Lundell L, Das R CRD summary This review concluded that 40mg esomeprazole appeared to have higher healing rates than licensed standard- and double-dose proton pump inhibitors, for severe erosive oesophagitis. The evidence presented appeared to support these conclusions, but the reliance on indirect mixed treatment comparisons and the poor reporting of trial characteristics, make it difficult to assess the reliability of the findings. Authors

DARE.2009

103. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis Latimer N, Lord J, Grant RL (...) of cyclooxygenase-2 selective inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), and both of these in combination with proton-pump inhibitors, in patients with osteoarthritis. The authors concluded that it was cost-effective to add a proton-pump inhibitor to treatment with either cyclooxygenase-2 inhibitors or NSAIDs. The analysis was generally well conducted and adequately reported and the authors' conclusions appear to be appropriate. Type of economic evaluation Cost-effectiveness analysis, cost

NHS Economic Evaluation Database.2009

104. Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI

Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI Article Text Aetiology Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI

Evidence-Based Medicine (Requires free registration)2009

105. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials

The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials Clark K, Lam LT, Gibson S, Currow D CRD summary The authors concluded that pre-medication of elective surgery patients (...) with ranitidine (histamine-2 blocker) was more effective than proton-pump inhibitors in reducing the volume of gastric secretions and reducing gastric acidity. The conclusions reflected the evidence presented, but should be interpreted with caution given the potential for publication bias, reviewer error and bias, and the limitations of small sample sizes. Authors' objectives To compare the effect of proton pump inhibitors with histamine-2 blockers on gastric secretions. Searching MEDLINE, EMBASE and CINHAL

DARE.2009

106. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis

Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis Pongprasobchai S, Kridkratoke S, Nopmaneejumruslers C CRD summary The review found a significantly lower rate of clinically important (...) bleeding when using proton pump inhibitors rather than histamine-2 receptor antagonists in the prevention of stress-related mucosal disease in critically ill patients. Rates of nosocomial pneumonia were similar. The reliability of the authors’ conclusions is unclear due to some methodological weaknesses and differences between the small number of studies. Authors' objectives To evaluate the effectiveness of proton pump inhibitors compared to histamine-2 receptor antagonists in the prevention of stress

DARE.2009

107. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis

The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis Gill SK, O'Brien L, Einarson TR, Koren G CRD summary This review concluded that proton pump inhibitor use during early pregnancy was not associated with an increased risk for major congenital birth defects, spontaneous abortions and preterm delivery. In light of uncertainty (...) over generalisability and parts of the review process, plus the potential influence of one large study, the reliability of the authors' conclusions is unclear. Authors' objectives To determine the foetal safety of proton pump inhibitors (PPIs) during early pregnancy. Searching MEDLINE, EMBASE, International Pharmaceutical Abstracts, EBM Reviews and CINAHL were searched without language restrictions from inception to July 2008; search terms were reported. Reference lists of relevant articles were

DARE.2009

108. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.

Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. 19150702 2009 01 19 2009 01 30 2015 06 16 1474-547X 373 9659 2009 Jan 17 Lancet (London, England) Lancet Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new (...) with new onset dyspepsia in primary care. Patients aged 18 years and older who consulted with their family doctor for new onset dyspepsia in the Netherlands were eligible for enrolment in this double-blind, randomised controlled trial. Between October, 2003, and January, 2006, 664 patients were randomly assigned to receive stepwise treatment with antacid, H(2)-receptor antagonist, and proton pump inhibitor (step-up; n=341), or these drugs in the reverse order (step-down; n=323), by use of a computer

Lancet2009

109. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. 19726078 2009 09 21 2009 10 02 2015 11 19 1474-547X 374 9694 2009 Sep 19 Lancet (London, England) Lancet Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. 989-97 10.1016/S0140-6736(09)61525-7 Proton-pump inhibitors (PPIs) are often prescribed (...) in combination with thienopyridines. Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel. In the PRINCIPLE-TIMI 44 trial, the primary outcome was inhibition of platelet aggregation at 6 h assessed by light-transmission aggregometry. In the TRITON-TIMI 38 trial, the primary endpoint was the composite of cardiovascular death

Lancet2009

110. Proton Pump Inhibitor Association with Increased Risk of Clostridium difficile Associated Diarrhea

Proton Pump Inhibitor Association with Increased Risk of Clostridium difficile Associated Diarrhea "Proton Pump Inhibitor Association with Increased Risk of Clostridium d" by Kitty Earley < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers MS, PA-C Second Advisor Rob Rosenow PharmD, OD Rights . Abstract Background: Proton Pump Inhibitor use is increasing in the hospital (...) has been proposed: Proton Pump Inhibitors (PPI). Hypothesis: Hypochlorhydria from PPI is a risk factor for developing CDAD. Study Design: Systematic review of available medical literature and reviews. Methods: An extensive literature search was conducted on Medline-OVID, CINAHL (EBSCOhost), and PubMed using the search terms “proton pump inhibitor and Clostridium difficile”, “Proton Pump Inhibitors”, and “Clostridium difficile”. Relevant references were retrieved and references from the reviewed

Pacific University EBM Capstone Project2009

111. Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients

Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients 18616516 2008 10 30 2009 02 20 2008 10 30 1365-2036 28 9 2008 Nov 01 Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients. 1147-58 10.1111/j.1365-2036.2008.03790.x Radiofrequency (RF) energy delivery is an endoscopic procedure developed (...) for the treatment of gastro-oesophageal reflux disease. To compare RF and a proton pump inhibitor strategy (PPI) in PPI-dependent patients by carrying out a prospective, randomized trial. Patients with PPI-dependent typical reflux symptoms were randomly allocated to either RF or PPI regimen alone. The primary endpoint, evaluated at 6-month, was defined as the possibility for the patient to stop or to decrease PPI use to <50% of the effective dose required at baseline. In the RF group, 18/20 patients stopped (n

EvidenceUpdates2008

112. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: `on` or `off` proton pump inhibitor?

Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: `on` or `off` proton pump inhibitor? 18684197 2008 10 15 2008 10 28 2008 10 15 1572-0241 103 10 2008 Oct The American journal of gastroenterology Am. J. Gastroenterol. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? 2446-53 10.1111/j.1572-0241.2008.02033.x In patients with proton pump inhibitor (PPI)-resistant symptoms, ambulatory 24 (...) -h pH-impedance monitoring can be used to assess whether a relationship exists between symptoms and reflux episodes. Until now, it is unclear whether combined pH-impedance monitoring in these patients should be performed on or off PPI. Thirty patients with symptoms of heartburn, chest pain, and/or regurgitation despite PPI twice daily underwent ambulatory 24-h pH-impedance monitoring twice, once on PPI and once after cessation of the PPI for 7 days. The order of the measurements was randomized

EvidenceUpdates2008

113. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication

Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication 18644011 2008 09 22 2008 12 05 2013 11 21 1365-2036 28 7 2008 Oct 01 Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. 868-77 10.1111/j.1365-2036.2008.03807.x The evidence on whether high-dose proton pump inhibitors (PPIs) increase cure rates (...) of Helicobacter pylori treatment has not been previously assessed. To evaluate the evidence on the usefulness of high-dose PPI in standard triple therapy by performing a systematic review and a meta-analysis. A systematic search was performed in multiple databases and in the abstracts submitted to the Digestive Diseases Week, the European Helicobacter Study Group congress and the United European Gastroenterology Week. Randomized trials comparing a standard dose of a PPI with high-dose PPI both twice a day

EvidenceUpdates2008

114. Proton-pump inhibitor use and the risk for community-acquired pneumonia.

Proton-pump inhibitor use and the risk for community-acquired pneumonia. BACKGROUND: Recent studies suggest that proton-pump inhibitors (PPIs) may increase the risk for community-acquired pneumonia (CAP). OBJECTIVE: To examine the association between PPI use and CAP in adults followed in general practices in the United Kingdom. DESIGN: Nested case-control study. SETTING: The General Practice Research Database (1987 to 2002) in the United Kingdom. PARTICIPANTS: Patients age 18 years or older (...) with at least 6 months of initial pneumonia-free follow-up in the database. Case patients (n = 80 066) were defined as those who received an incident diagnosis of CAP. Control participants (n = 799 881) were selected by using incidence density sampling, matching on practice site, calendar period, and follow-up duration. MEASUREMENTS: Use of PPIs within 30 days before the index date. Adjusted odds ratios (ORs) were estimated by using conditional logistic regression, adjusting for potential confounders

Annals of Internal Medicine2008

115. Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia

Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia Article Text Therapeutics Review: prokinetics, histamine H 2 receptor

Evidence-Based Medicine (Requires free registration)2008

116. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial)

Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial) Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial) Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled (...) daily, clarithromycin 250mg twice daily, and metronidazole 400mg twice daily, for one week, followed by three weeks of omeprazole 20mg once daily), and proton pump inhibitor alone (omeprazole 20mg once daily for four weeks). Location/setting UK/primary care. Methods Analytical approach: This economic evaluation was based on a single study. The time horizon was one year and the authors did not explicitly report the study perspective. Effectiveness data: The clinical data were derived from

NHS Economic Evaluation Database.2008

117. The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis

The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a (...) with the proton-pump inhibitor (PPI) omeprazole and laparoscopic Nissen fundoplication in the management of patients with long-term gastro-oesophageal reflux disease. The authors concluded that PPIs were the cost-effective option when symptom-free months and quality-adjusted life-years were used as benefit measures. In summary, with a few exceptions, the methods were transparent and clearly reported. The authors’ conclusions appear to be appropriate. Type of economic evaluation Cost-effectiveness analysis, cost-utility

NHS Economic Evaluation Database.2008

118. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention

Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Saini S D, Schoenfeld P, Fendrick A M, Scheiman J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of long-term therapy with low-dose aspirin (ASA) plus proton-pump inhibitor (PPI) co-therapy, compared with ASA alone, for the prevention of upper gastrointestinal bleeding

NHS Economic Evaluation Database.2008

119. Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial

Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial Mason J M, Raghunath A S, Hungin A P, Jackson W Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the clinical and economic impact of Helicobacter pylori eradication in long-term users of proton pump inhibitors in comparison with no eradication. The authors concluded that eradication

NHS Economic Evaluation Database.2008

120. Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants

Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Gieruszczak-Bialek D, Skorka A, Szajewska H CRD summary The review evaluated the safety and effectiveness of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease in infants (...) and found limited evidence that omeprazole significantly reduced reflux. The review was generally well conducted. The authors’ conclusion that there was insufficient evidence for the use of proton pump inhibitors for treatment of gastro-oesophageal reflux disease in infants seems reliable. Authors' objectives To evaluate the safety and effectiveness of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease (GORD) in infants. Searching MEDLINE (1966-2007), EMBASE (1980-2007

DARE.2008